LEADER 04376nam 2201033z- 450 001 9910557675503321 005 20231214132918.0 035 $a(CKB)5400000000044778 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77128 035 $a(EXLCZ)995400000000044778 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAdvanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (207 p.) 311 $a3-0365-2611-0 311 $a3-0365-2610-2 330 $aThe concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. These intend to offer not only regeneration, but complete functional recovery of diseased tissues and organs using different strategies. Gene therapy, cell therapy and tissue engineering are the main areas in which promising advanced therapies are emerging. The eye is a very complex organ whose main structures, the cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs by fighting against the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds and cell stemness, among others?not to mention the complicated legislation around ATMPs, the complexity in production and quality control and the absence of standardized protocols.The purpose of this Special Issue is to serve as an overview of the current progress in the application of cell and gene therapies, as well as tissue engineering to restore functionality in diseased ocular structures, and the challenges linked to reaching patients. 517 $aAdvanced Therapy Medicinal Products for Eye Diseases 606 $aMedicine$2bicssc 610 $aMPC polymer 610 $adry eye 610 $aocular surface 610 $alacrimal fluid 610 $amucin 610 $a3D bioprinting 610 $acornea 610 $aretina 610 $aophthalmology 610 $atissue regeneration 610 $aelectrospinning 610 $aconjunctiva 610 $adecellularized tissue matrix 610 $asmall intestinal submucosa 610 $aurinary bladder matrix 610 $apolycaprolactone 610 $afiber 610 $atissue engineering 610 $astratification 610 $aconjunctival epithelial cells 610 $ahydrogel 610 $akeratoplasty 610 $ascaffold 610 $acollagen 610 $aadvanced therapy medicinal product 610 $aATMP 610 $acell therapy 610 $agene therapy 610 $aeye 610 $aocular 610 $aregulatory 610 $amarketing authorization 610 $adouble-crosslinking 610 $acarbodiimide 610 $aglutaraldehyde 610 $asodium metabisulfite 610 $asodium borohydride 610 $aEDC/NHS 610 $astem cells 610 $aretinal diseases 610 $aoptic nerve diseases 610 $acell replacement 610 $acell sources 610 $aadvanced therapies 610 $aocular mucosa 610 $ablindness 610 $aCLET 610 $alimbal niche 610 $alimbal stem cell 610 $aLSCD 610 $amesenchymal stem cell transplantation 610 $aMSCT 610 $acorneal limbus 610 $adecellularized xenograft 610 $arecellularization 610 $amesenchymal stem cells 615 7$aMedicine 700 $aDiebold$b Yolanda$4edt$01304472 702 $aGarci?a-Posadas$b Laura$4edt 702 $aDiebold$b Yolanda$4oth 702 $aGarci?a-Posadas$b Laura$4oth 906 $aBOOK 912 $a9910557675503321 996 $aAdvanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges$93027459 997 $aUNINA